Abstract
The rapid development of new therapeutic agents that target specific molecular pathways involved in tumour cell proliferation provides an unprecedented opportunity to achieve a much higher degree of biochemical specificity than previously possible with traditional chemotherapeutic anticancer agents. However, the lack of specificity of these established chemotherapeutic drugs allowed a relatively straightforward approach to their use in combination therapies. Developing a paradigm for combining new, molecularly targeted agents, on the other hand, is substantially more complex. The abundance of molecular data makes it possible, at least in theory, to predict how such agents might interact across crucial growth control networks. Initial strategies to examine molecularly targeted agent combinations have produced a small number of successes in the clinic. However, for most of these combination strategies, both in preclinical models and in patients, it is not clear whether the agents being combined actually hit their targets to induce growth inhibition. Here, we consider the initial approach of the US National Cancer Institute (NCI) to the evaluation of combinations of molecularly targeted anticancer agents in patients and provide a description of several new approaches that the NCI has initiated to improve the effectiveness of combination-targeted therapy for cancer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Murgo, A. J., Kummar, S., Gutierrez, M., Tomaszewski, J. E. & Doroshow, J. H. in Abeloff's Clinical Oncology (eds Abeloff, M. D., Armitage, J. O., Niederhuber, J. E., Kastan, M. B. & McKenna, W. G) 485–500 (Churchill Livingstone, Philadelphia, 2008).
Druker, B. J. Perspectives on the development of imatinib and the future of cancer research. Nature Med. 15, 1149–1152 (2009).
Joensuu, H. et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N. Engl. J. Med. 344, 1052–1056 (2001).
Vogel, C. L. et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 20, 719–726 (2002).
Jones, S. et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321, 1801–1806 (2008).
Parmigiani, G. et al. Design and analysis issues in genome-wide somatic mutation studies of cancer. Genomics 93, 17–21 (2009).
Frei, E. III. Combination cancer therapy: presidential address. Cancer Res. 32, 2593–2607 (1972).
DeVita, V. T. & Schein, P. S. The use of drugs in combination for the treatment of cancer: rationale and results. N. Engl. J. Med. 288, 998–1006 (1973).
DeVita, V. T. Jr, Young, R. C. & Canellos, G. P. Combination versus single agent chemotherapy: a review of the basis for selection of drug treatment of cancer. Cancer 35, 98–110 (1975).
Doroshow, J. H. & Synold, T. in Thomas' Hematopoietic Cell Transplantation (eds Blume, K. G., Forman, S. J. & Appelbaum, F. R) 130–157 (Blackwell Publishing, Malden, Massachusetts, 2004).
Wen, P. Y. et al. Phase I/II study of sorafenib and temsirolimus for patients with recurrent glioblastoma (GBM)(NABTC 05–02). J. Clin. Oncol. 27 (Suppl. 15), 2006 (2009).
Herbst, R. S. et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial–INTACT 2. J. Clin. Oncol. 22, 785–794 (2004).
Hait, W. N. & Hambley, T. W. Targeted cancer therapeutics. Cancer Res. 69, 1263–1267 (2009).
McDermott, U., Pusapati, R. V., Christensen, J. G., Gray, N. S. & Settleman, J. Acquired resistance of non-small cell lung cancer cells to MET kinase inhibition is mediated by a switch to epidermal growth factor receptor dependency. Cancer Res. 70, 1625–1634 (2010).
Tomaszewski, J. E. & Doroshow, J. H. in Cancer Drug Discovery and Development: Molecular Targeting in Oncology (eds Kaufman, H. L., Wadler, S. & Antman, K) 703–718 (Humana Press, Totowa, New Jersey, 2008).
Holbeck, S., Collins, J. M. & Doroshow, J. H. Analysis of FDA-approved anti-cancer agents in the NCI60 panel of human tumor cell lines. Mol. Cancer Ther. 9, 1451–1460 (2010).
Kinders, R. J. et al. Preclinical modeling of a Phase 0 clinical trial: qualification of a pharmacodynamic assay of poly (ADP-ribose) polymerase in tumor biopsies of mouse xenografts. Clin. Cancer Res. 14, 6877–6885 (2008).
Sarker, D. & Workman, P. Pharmacodynamic biomarkers for molecular cancer therapeutics. Adv. Cancer Res. 96, 213–268 (2007).
Doroshow, J. H. & Parchment, R. E. Oncologic Phase 0 trials incorporating clinical pharmacodynamics: from concept to patient. Clin. Cancer Res. 14, 3658–3663 (2008).
Dancey, J. E. & Chen, H. X. Strategies for optimizing combinations of molecularly targeted anticancer agents. Nature Rev. Drug Discov. 5, 649–659 (2006).
Azad, N. S. et al. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J. Clin. Oncol. 26, 3709–3714 (2008).
Sosman, J. A. et al. Updated results of Phase I trial of sorafenib (S) and bevacizumab (B) in patients with metastatic renal cell cancer (mRCC). J. Clin. Oncol. 26 (Suppl. 15), 5011 (2008).
Burger, R. A., Sill, M. W., Monk, B. J., Greer, B. E. & Sorosky, J. I. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J. Clin. Oncol. 25, 5165–5171 (2007).
Cannistra, S. A. et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J. Clin. Oncol. 25, 5180–5186 (2007).
Matei, D., Sill, M. W., DeGeest, K. & Bristow, R. E. Phase II trial of sorafenib in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC): A Gynecologic Oncology Group (GOG) study. J. Clin. Oncol 26 (Suppl. 15), 5537 (2008).
Feldman, D. R. et al. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 27, 1432–1439 (2009).
Rini, B. I. et al. A phase I study of sunitinib plus bevacizumab in advanced solid tumors. Clin. Cancer Res. 15, 6277–6283 (2009).
Motzer, R. J. et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295, 2516–2524 (2006).
Villaume, K. et al. VEGF secretion by neuroendocrine tumor cells is inhibited by octreotide and by inhibitors of the PI3K/AKT/mTOR pathway. Neuroendocrinology 91, 268–278 (2010).
Huynh, H. et al. Bevacizumab and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma. J. Hepatol. 49, 52–60 (2008).
Huynh, H., Teo, C. C. & Soo, K. C. Bevacizumab and rapamycin inhibit tumor growth in peritoneal model of human ovarian cancer. Mol. Cancer Ther. 6, 2959–2966 (2007).
Stephan, S. et al. Effect of rapamycin alone and in combination with antiangiogenesis therapy in an orthotopic model of human pancreatic cancer. Clin. Cancer Res. 10, 6993–7000 (2004).
Merchan, J. R. et al. Phase I/II trial of CCI-779 and bevacizumab in stage IV renal cell carcinoma: Phase I safety and activity results. J. Clin. Oncol. 25 (Suppl. 18), 5034 (2007).
Zafar, Y. et al. Preliminary results of a Phase I study of bevacizumab (BV) in combination with everolimus (E) in patients with advanced solid tumors. J. Clin. Oncol. 24 (Suppl. 18), 3097 (2006).
Hainsworth, J. D. et al. Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma. J. Clin. Oncol. 28, 2131–2136 (2010).
Yang, J. C. et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. 349, 427–434 (2003).
Whorf, R. C. et al. Phase II study of bevacizumab and everolimus (RAD001) in the treatment of advanced renal cell carcinoma (RCC). J. Clin. Oncol. 26 (Suppl. 15), 5010 (2008).
Atkins, M. B. et al. Randomized Phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J. Clin. Oncol. 22, 909–918 (2004).
Patel, P. H., Senico, P. L., Curiel, R. E. & Motzer, R. J. Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma. Clin. Genitourin. Cancer 7, 24–27 (2009).
Patnaik, A. et al. A Phase I, pharmacokinetic and pharmacodynamic study of sorafenib (S), a multi-targeted kinase inhibitor in combination with temsirolimus (T), an mTOR inhibitor in patients with advanced solid malignancies. J. Clin. Oncol. 25 (Suppl.18), 3512 (2007).
Chang, S. M. et al. Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas (MG)(NABTC 04–02). J. Clin. Oncol. 27 (Suppl. 15), 2004 (2009).
Prados, M. et al. Phase I/II study of sorefenib and erlotinib for patients with recurrent glioblastoma (GBM)(NABTC 05–02). J. Clin. Oncol. 27 (Suppl. 15), 2005 (2009).
Kim, K. B. et al. Phase I/II study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma. J. Clin. Oncol. 27 (Suppl. 15), 9026 (2009).
Miller, V. A., Das, A. & Rossi, M. A randomized, double-blind, placebo-controlled, Phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). J. Clin. Oncol. 27 (Suppl.15), LBA8002 (2009).
Kindler, H. L. et al. Final analysis of a randomized Phase II study of bevacizumab (B) and gemcitabine (G) plus cetuximab (C) or erlotinib (E) in patients (pts) with advanced pancreatic cancer (PC). J. Clin. Oncol. 26 (Suppl. 15), 4502 (2008).
Dickler, M. et al. Phase II trial of erlotinib (OSI-774), an epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor, and bevacizumab, a recombinant humanized monoclonal antibody to vascular endothelial growth factor (VEGF), in patients (pts) with metastatic breast cancer (MBC). J. Clin. Oncol. 22 (Suppl. 14), 2001 (2004).
Bukowski, R. M. et al. Randomized Phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J. Clin. Oncol. 25, 4536–4541 (2007).
Saltz, L. B. et al. Randomized Phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J. Clin. Oncol. 25, 4557–4561 (2007).
Hecht, J. R. et al. A randomized Phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J. Clin. Oncol. 27, 672–680 (2009).
Tol, J. et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N. Engl. J. Med. 360, 563–572 (2009).
Turner, N. C. et al. A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor. EMBO J. 27, 1368–1377 (2008).
Wiltshire, T. D. et al. Sensitivity to poly (ADP-ribose) polymerase (PARP) inhibition identifies ubiquitin specific peptidase 11 (USP11) as a regulator of DNA double-strand break repair. J. Biol. Chem. 285, 14565–14571 (2010).
Azorsa, D. O. et al. Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer. J. Transl. Med. 7, 43 (2009).
Whitehurst, A. W. et al. Synthetic lethal screen identification of chemosensitizer loci in cancer cells. Nature 446, 815–819 (2007).
Zeitlin, B. D., Ellis, L. M. & Nor, J. E. Inhibition of vascular endothelial growth factor receptor-1/Wnt/β-catenin crosstalk leads to tumor cell death. Clin. Cancer Res. 15, 7453–7455 (2009).
Naik, S., Dothager, R. S., Marasa, J., Lewis, C. L. & Piwnica-Worms, D. Vascular endothelial growth factor receptor-1 is synthetic lethal to aberrant β-catenin activation in colon cancer. Clin. Cancer Res. 15, 7529–7537 (2009).
Luo, J. et al. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 137, 835–848 (2009).
Bommi-Reddy, A. et al. Kinase requirements in human cells: III. Altered kinase requirements in VHL−/− cancer cells detected in a pilot synthetic lethal screen. Proc. Natl Acad. Sci. USA 105, 16484–16489 (2008).
Lehar, J., Stockwell, B. R., Giaever, G. & Nislow, C. Combination chemical genetics. Nature Chem. Biol. 4, 674–681 (2008).
Perlman, Z. E. et al. Multidimensional drug profiling by automated microscopy. Science 306, 1194–1198 (2004).
Borisy, A. A. et al. Systematic discovery of multicomponent therapeutics. Proc. Natl Acad. Sci. USA 100, 7977–7982 (2003).
Shoemaker, R. H. The NCI60 human tumour cell line anticancer drug screen. Nature Rev. Cancer 6, 813–823 (2006).
Herberger, B. et al. Simultaneous blockade of the epidermal growth factor receptor/mammalian target of rapamycin pathway by epidermal growth factor receptor inhibitors and rapamycin results in reduced cell growth and survival in biliary tract cancer cells. Mol. Cancer Ther. 8, 1547–1556 (2009).
Reardon, D. A. et al. Phase II trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. J. Neurooncol. 96, 219–230 (2010).
Johnson, J. I. et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br. J. Cancer 84, 1424–1431 (2001).
Decker, S. & Sausville, E. A. Preclinical modeling of combination treatments: fantasy or requirement? Ann. NY Acad. Sci. 1059, 61–69 (2005).
Houghton, P. J. et al. Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing Program. Mol. Cancer Ther. 9, 101–112 (2010).
Kummar, S. et al. Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. J. Clin. Oncol. 27, 2705–2711 (2009).
Murgo, A. J. et al. Designing phase 0 cancer clinical trials. Clin. Cancer Res. 14, 3675–3682 (2008).
Tan, D. S. et al. Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development. Cancer J. 15, 406–420 (2009).
Carden, C. P. et al. Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development? Drug Discov. Today 15, 88–97 (2010).
Kummar, S. et al. Compressing drug development timelines in oncology using phase '0' trials. Nature Rev. Cancer 7, 131–139 (2007).
Wan, X., Harkavy, B., Shen, N., Grohar, P. & Helman, L. J. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 26, 1932–1940 (2007).
Ganter, B., Zidek, N., Hewitt, P. R., Muller, D. & Vladimirova, A. Pathway analysis tools and toxicogenomics reference databases for risk assessment. Pharmacogenomics 9, 35–54 (2008).
Barros, S. A. & Martin, R. B. Predictive toxicogenomics in preclinical discovery. Methods Mol. Biol. 460, 89–112 (2008).
Hambley, T. W. & Hait, W. N. Is anticancer drug development heading in the right direction? Cancer Res. 69, 1259–1262 (2009).
Kwak, E. L., Clark, J. W. & Chabner, B. Targeted agents: the rules of combination. Clin. Cancer Res. 13, 5232–5237 (2007).
Puzanov, I. et al. Final results of a Phase I trial of sorafenib and bevacizumab in patients with metastatic renal cell cancer (mRCC). Proc. AACR-NCI-EORTC Int. Conf. Molec. Targets Cancer Ther. Abstr. A19 (2007).
Hong, D. S. et al. Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies. Clin. Cancer Res. 15, 7061–7068 (2009).
Riechelmann, R. P. et al. Sorafenib for metastatic renal cancer: the Princess Margaret experience. Am. J. Clin. Oncol. 31, 182–187 (2008).
Blackwell, K. L. et al. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J. Clin. Oncol. 28, 1124–1130 (2010).
Merchan, J. R. et al. Phase I/II trial of CCI 779 and bevacizumab in advanced renal cell carcinoma (RCC): Safety and activity in RTKI refractory RCC patients. J. Clin. Oncol. 27 (Suppl. 15), 5039 (2009).
Hudes, G. et al. Temsirolimus, interferon α, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 356, 2271–2281 (2007).
Motzer, R. J. et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled Phase III trial. Lancet 372, 449–456 (2008).
Herbst, R. S. et al. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J. Clin. Oncol. 25, 4743–4750 (2007).
Shepherd, F. A. et al. Efficacy of erlotinib in previously treated non-small-cell lung cancer: a trial of the National Cancer Institute of Canada, Clinical Trials Group. N. Engl. J. Med. 353, 123–132 (2005).
Cunningham, D. et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 351, 337–345 (2004).
Giantonio, B. J. et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J. Clin. Oncol. 25, 1539–1544 (2007).
Arteaga, C. L. et al. A Phase I-II study of combined blockade of the ErbB receptor network with trastuzumab and gefitinib in patients with HER2 (ErbB2)-overexpressing metastatic breast cancer. Clin. Cancer Res. 14, 6277–6283 (2008).
Escudier, B. et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356, 125–134 (2007).
Acknowledgements
The authors wish to express their appreciation to the members of the National Cancer Institute's Cancer Therapy Evaluation Program who have overseen the clinical trials described in this paper and the members of the National Cancer Institute's Developmental Therapeutics Program who have had an essential role in coordinating the initiatives outlined in the paper. This work was supported by federal funds from the National Cancer Institute, National Institutes of Health. The content of this publication does not necessarily reflect the views or the policies of the US Department of Health and Human Services nor does the mention of trade names, commercial products or organizations imply endorsement by the US government.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Related links
Rights and permissions
About this article
Cite this article
Kummar, S., Chen, H., Wright, J. et al. Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements. Nat Rev Drug Discov 9, 843–856 (2010). https://doi.org/10.1038/nrd3216
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd3216
This article is cited by
-
Interpreting drug synergy in breast cancer with deep learning using target-protein inhibition profiles
BioData Mining (2024)
-
Clinical results of the EVESOR trial, a multiparameter phase I trial of everolimus and sorafenib combination in solid tumors
Cancer Chemotherapy and Pharmacology (2023)
-
Emerging strategies to overcome resistance to third-generation EGFR inhibitors
Journal of Hematology & Oncology (2022)
-
Telomerase-targeting compounds Imetelstat and 6-thio-dG act synergistically with chemotherapy in high-risk neuroblastoma models
Cellular Oncology (2022)
-
Synthetic lethality and synergetic effect: the effective strategies for therapy of IDH-mutated cancers
Journal of Experimental & Clinical Cancer Research (2021)